Filter by patients with: All

3 patient evaluations for Olmesartan with a side effects rating of None

30 members have decided to share their profiles only with other members of PatientsLikeMe.

Sort by: Most recent

Apr 12, 2012 (Started Nov 05, 2009)

  • Effectiveness
    Moderate (for elevated blood pressure)
  • Side effects
    None
  • Adherence
    Usually
  • Burden
    Not at all hard to take
Dosage: 20 mg Daily
  • 0 helpful marks

Dec 10, 2011 (Started Oct 05, 2009)

  • Effectiveness
    Major (for Support heart health)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Cost: < $25 monthly

Nov 22, 2011 (Started Oct 05, 2009)

  • Effectiveness
    Moderate (for Support heart health)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Cost: < $25 monthly

Nov 6, 2011 (Started Oct 05, 2009)

  • Effectiveness
    Moderate (for Support heart health)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 10 mg Daily
Cost: < $25 monthly

Sep 28, 2011 (Started Oct 05, 2009)

  • Effectiveness
    Moderate (for Support heart health)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 10 mg Daily
Cost: < $25 monthly

Aug 15, 2011 (Started Oct 05, 2009)

  • Effectiveness
    Major (for Support heart health)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 10 mg Daily
Cost: < $25 monthly

Jul 21, 2011 (Started Oct 05, 2009)

  • Effectiveness
    Moderate (for Support heart health)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 10 mg Daily
Cost: < $25 monthly
  • 0 helpful marks

May 23, 2010 (Started Jan 01, 2009)

  • Effectiveness
    Can't tell (for elevated blood pressure)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 20 mg Daily
Cost: < $25 monthly
  • 0 helpful marks
Last updated:
Showing 3 of 3 patient evaluations for Olmesartan